AbbVie's oral RA candidate meets in Japanese Phase IIb/III trial

AbbVie Inc. (NYSE:ABBV) said all three doses of once-daily oral upadacitinib (ABT-494) met the primary endpoint in the Japanese Phase IIb/III SELECT-SUNRISE trial to treat moderate to severe rheumatoid arthritis in patients who were on a

Read the full 363 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE